Hanoll Phosphoren Injection 500 milligrams (Cefazedone Sodium)

Adult administration

As cefazolin sodium, for infections caused by Gram-positive bacteria, administer 1 to 2 g (activity) intravenously divided into 2 to 3 doses per day. For infections caused by Gram-negative bacteria, administer 3 to 4 g (activity) intravenously divided into 2 to 3 doses per day. In cases of life-threatening infections or infections caused by moderately susceptible bacteria, the dose can be increased up to 6 g (activity) per day. For patients with renal dysfunction, the dosage and dosing interval should be determined based on the degree of renal impairment.

This medication should not be used in patients with allergies to cephalosporin antibiotics. It is particularly safe not to administer it to premature infants and neonates. Caution is needed for pregnant women in the first three months of pregnancy, as well as for patients with kidney or liver function issues. It should be used carefully in patients with hemophilia or thrombocytopenia, as well as in patients with gastrointestinal ulcers. Patients who have difficulty with oral intake or are receiving parenteral nutrition, the elderly, or patients in poor general condition may show symptoms of vitamin K deficiency and should be closely monitored. Mild hypersensitivity reactions such as headaches, dizziness, and nausea may occur with the use of this medication, and rarely, skin rashes, fever, or severe allergic reactions may occur. If any symptoms occur, the use of the medication should be stopped immediately, and consultation with a healthcare professional should be sought. Liver function tests may temporarily increase, and leukopenia may occur, so regular blood tests are recommended. Severe colitis or abdominal pain, diarrhea, nausea, vomiting, and loss of appetite can occur in the gastrointestinal system, and if such symptoms arise, healthcare professionals should be notified immediately. Respiratory symptoms such as pneumonia or difficulty breathing may rarely occur and should be observed carefully. The phenomenon of fungal superinfection, such as oral inflammation or candidiasis, may also occur. Symptoms of vitamin K and vitamin B complex deficiency may appear, so nutritional status should be well managed. It is important to use this medication only for an appropriate period as determined by susceptibility testing to prevent the emergence of resistant bacteria. Prior to administration, a medical history and skin reaction test is recommended to check for allergic reactions, and the patient's condition should be sufficiently observed during treatment. Considering the increasing resistance to first-generation cephalosporin antibiotics, susceptibility test results should be referred to. When used alongside aminoglycoside antibiotics or certain diuretics, or high-dose anticoagulants, there may be an increased risk of renal function impairment or bleeding, requiring careful monitoring. Nursing women should use this medication cautiously as small amounts may be transmitted through breast milk. Finally, this medication should not be mixed and injected with aminoglycoside antibiotics within the same syringe.

Serious side effects

• Skin rash
• anaphylaxis
• fever
• coughing
• difficulty breathing
• interstitial pneumonia
• PIE syndrome.

Mild side effects

• Mild headache
• dizziness
• nausea
• skin rash
• fever
• anaphylaxis
• increased AL-P
• GOT
• GPT
• transient leukopenia

This medication should be stored in a tightly sealed container to protect it from air and moisture, and it is best kept at room temperature between 1 and 30 degrees Celsius. Storing it this way helps maintain the medication's efficacy and prevents degradation.

Appearance

A colorless transparent vial filled with a white to pale yellow powder

Package unit

500mg/vial x 50 vials